Annals of Oncology 28: 2900, 2017 doi:10.1093/annonc/mdw269 Published online 30 August 2016
CORRIGENDUM
SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study M. Sinn, B. V. Sinn, J. K. Striefler, J. L. Lindner, J. M. Stieler, P. Lohneis, S. Bischoff, H. Bla¨ker, U. Pelzer, M. Bahra, M. Dietel, B. Do¨rken, H. Oettle, H. Riess & C. Denkert Ann Oncol 2014; 25: 1025–1032 (doi:10.1093/annonc/mdu084) In Table 1 (patient characteristics), cytoplasmic SPARC “high” is defined as IRS >¼ 0, as described in the first paragraph of the results section.
However, the authors’ intention was to illustrate the patient characteristics in the table according to the stratification used in the subsequent survival analyses (with cytoplasmic SPARC “high” defined as IRS >¼ 3). A corrected version of the table is presented here.
Stromal SPARC Overall
Age median 62 range 36–81 Survival (months) Median DFS (95% CI) 11.2 (9.2–13.3) Median OS (95% CI) 21.5 (17.6–25.4) Karnofsky Performance Status Scale Score median 80 range 50–100 n ¼ (%) Treatment Arm Gemcitabine 90 Observation 70 Gender Female 65 Male 95 T stage pT1–2 16 pT3–4 144 Nodal status pN0 36 pN1 124 Grading G1–2 92 G3 65 missing 3 Resection margin R0 130 R1 30
Cytoplasmic SPARC
High n 5 93 (58.1%)
Low n 5 67 (41.9%)
High n 5 42 (26.3%)
Low n 5 118 (73.8%)
63 36–81
62 37–74
65.5 40–81
61 36–79
9.0 (5.4–12.5) 19.8 (14.0–25.7)
12.6 (9.0–16.2) 26.6 (17.2–36.1)
7.4 (4.6–10.2) 14.1 (7.7–20.4)
12.1 (10.2–13.9) 25.6 (18.8–32.5)
80 50–100 n ¼ (%)
80 60–100 n ¼ (%)
80 60–100 n ¼ (%)
85 50–100 n ¼ (%)
46 (51.1) 47 (67.1)
44 (48.9) 23 (32.9)
26 (28.9) 16 (22.9)
64 (71.1) 54 (77.1)
39 (60.0) 54 (56.8)
26 (40.0) 41 (43.2)
17 (26.2) 25 (26.3)
48 (73.8) 70 (73.7)
10 (62.5) 83 (57.6)
6 (37.5) 61 (42.2)
6 (37.5) 36 (25.0)
10 (62.5) 108 (75.0)
21 (58.3) 72 (58.1)
15 (41.7) 52 (41.9)
15 (41.7) 27 (21.8)
21 (58.3) 97 (78.2)
51 (55.4) 40 (61.5)
41 (44.6) 52 (38.5)
21 (22.8) 20 (30.8)
71 (77.2) 45 (69.2)
75 (57.7) 18 (60.0)
55 (42.4) 12 (40.0)
38 (29.2) 4 (13.3)
92 (70.8) 26 (86.7)
C The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email:
[email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/28/11/2900/3062456 by guest on 06 March 2018
